Lung cancer study seeks to unlock why immunotherapy fails in some patients
NCT ID NCT07637474
First seen Jun 09, 2026 · Last updated Jun 19, 2026 · Updated 2 times
Summary
This study looks at how the body's metabolism may influence whether immunotherapy works for people with non-small cell lung cancer. Researchers will collect and analyze tissue samples from 150 patients to compare those who respond to treatment with those who don't. The goal is to find biological markers that could predict response and discover new ways to make immunotherapy more effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS National Cancer institute
RECRUITINGRome, Rome, 00144, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could identify new biomarkers to predict which lung cancer patients will benefit from immunotherapy, and point toward new drug targets to overcome resistance.
What could go wrong
This is an observational study, not a treatment trial. It will not directly test any new therapy, and findings may not lead to immediate clinical changes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.